These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29171319)

  • 1. Cost-effectiveness of TYRX absorbable antibacterial envelope for prevention of cardiovascular implantable electronic device infection.
    Kay G; Eby EL; Brown B; Lyon J; Eggington S; Kumar G; Fenwick E; Sohail MR; Wright DJ
    J Med Econ; 2018 Mar; 21(3):294-300. PubMed ID: 29171319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial Envelope Is Associated With Low Infection Rates After Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Replacement: Results of the Citadel and Centurion Studies.
    Henrikson CA; Sohail MR; Acosta H; Johnson EE; Rosenthal L; Pachulski R; Dan D; Paladino W; Khairallah FS; Gleed K; Hanna I; Cheng A; Lexcen DR; Simons GR
    JACC Clin Electrophysiol; 2017 Oct; 3(10):1158-1167. PubMed ID: 29759500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial.
    Wilkoff BL; Boriani G; Mittal S; Poole JE; Kennergren C; Corey GR; Krahn AD; Schloss EJ; Gallastegui JL; Pickett RA; Evonich RF; Roark SF; Sorrentino DM; Sholevar DP; Cronin EM; Berman BJ; Riggio DW; Khan HH; Silver MT; Collier J; Eldadah Z; Holbrook R; Lande JD; Lexcen DR; Seshadri S; Tarakji KG
    Circ Arrhythm Electrophysiol; 2020 Oct; 13(10):e008503. PubMed ID: 32915063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic impact of introducing TYRX amongst patients with heart failure and reduced ejection fraction undergoing implanted cardiac device procedures: a retrospective model based cost analysis.
    Burnhope E; Rodriguez-Guadarrama Y; Waring M; Guilder A; Malhotra B; Razavi R; Rinaldi CA; Pennington M; Carr-White G
    J Med Econ; 2019 May; 22(5):464-470. PubMed ID: 30744444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England.
    Boriani G; Kennergren C; Tarakji KG; Wright DJ; Ahmed FZ; McComb JM; Goette A; Blum T; Biffi M; Green M; Shore J; Carion PL; Wilkoff BL
    Value Health; 2021 Jul; 24(7):930-938. PubMed ID: 34243836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of an antibacterial envelope for infection prevention in patients undergoing cardiac resynchronization therapy reoperations in Denmark.
    Frausing MHJP; Johansen JB; Afonso D; Jørgensen OD; Olsen T; Gerdes C; Johansen ML; Wolff C; Mealing S; Nielsen JC; Kronborg MB
    Europace; 2023 Jun; 25(6):. PubMed ID: 37345858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of an absorbable antibiotic envelope for prevention of cardiac implantable electronic device infection.
    Rennert-May E; Raj SR; Leal J; Exner DV; Manns BJ; Chew DS
    Europace; 2021 May; 23(5):767-774. PubMed ID: 33554239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Worldwide Randomized Antibiotic EnveloPe Infection PrevenTion Trial (WRAP-IT).
    Tarakji KG; Mittal S; Kennergren C; Corey R; Poole J; Stromberg K; Lexcen DR; Wilkoff BL
    Am Heart J; 2016 Oct; 180():12-21. PubMed ID: 27659878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of antibacterial envelope use in prevention of cardiovascular implantable electronic device infection.
    Ali S; Kanjwal Y; Bruhl SR; Alo M; Taleb M; Ali SS; Kabour A; Khawaja O
    Ther Adv Infect Dis; 2017 May; 4(3):75-82. PubMed ID: 28634537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between cardiac implantable electronic device envelopes evaluated in an animal model.
    Ip JE; Xu L; Lerman BB
    J Cardiovasc Electrophysiol; 2021 May; 32(5):1346-1354. PubMed ID: 33010088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of Cardiac Implantable Electronic Device-Related Infection in Patients With Cancer: The Role of a Comprehensive Prophylactic Bundle Approach That Includes the Antimicrobial Mesh.
    Khalil M; Karimzad K; Durand JB; Malek AE; Raad II; Viola GM
    Open Forum Infect Dis; 2020 Nov; 7(11):ofaa433. PubMed ID: 33204750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk profiles and outcomes of patients receiving antibacterial cardiovascular implantable electronic device envelopes: A retrospective analysis.
    Woodard DA; Kim G; Nilsson KR
    World J Cardiol; 2022 Mar; 14(3):177-186. PubMed ID: 35432770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Antibiotic-Eluting Envelope for Prevention of Cardiac Implantable Electronic Device Infections in Heart Failure.
    Modi RM; Liu CL; Isaza N; Raber I; Calvachi P; Zimetbaum P; Bellows BK; Kramer DB; Kazi DS
    Circ Cardiovasc Qual Outcomes; 2022 Mar; 15(3):e008443. PubMed ID: 35105176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the antibacterial envelope to prevent cardiac implantable electronic device infection in a high-risk population.
    Chaudhry U; Borgquist R; Smith JG; Mörtsell D
    Europace; 2022 Dec; 24(12):1973-1980. PubMed ID: 35989511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The World-wide Randomized Antibiotic Envelope Infection Prevention (WRAP-IT) trial: Long-term follow-up.
    Mittal S; Wilkoff BL; Kennergren C; Poole JE; Corey R; Bracke FA; Curnis A; Addo K; Martinez-Arraras J; Issa ZF; Redpath C; Moubarak J; Khelae SK; Boersma LVA; Korantzopoulos P; Krueger J; Lande JD; Morss GM; Seshadri S; Tarakji KG
    Heart Rhythm; 2020 Jul; 17(7):1115-1122. PubMed ID: 32087357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective comparative analysis of cardiovascular implantable electronic device infections with and without the use of antibacterial envelopes.
    Hassoun A; Thottacherry ED; Raja M; Scully M; Azarbal A
    J Hosp Infect; 2017 Mar; 95(3):286-291. PubMed ID: 28131641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of national mandatory screening of all admissions to English National Health Service hospitals for meticillin-resistant Staphylococcus aureus: a mathematical modelling study.
    Robotham JV; Deeny SR; Fuller C; Hopkins S; Cookson B; Stone S
    Lancet Infect Dis; 2016 Mar; 16(3):348-56. PubMed ID: 26616206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infectious consequences of hematoma from cardiac implantable electronic device procedures and the role of the antibiotic envelope: A WRAP-IT trial analysis.
    Tarakji KG; Korantzopoulos P; Philippon F; Biffi M; Mittal S; Poole JE; Kennergren C; Lexcen DR; Lande JD; Seshadri S; Wilkoff BL
    Heart Rhythm; 2021 Dec; 18(12):2080-2086. PubMed ID: 34280568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BLISTER Score: A Novel, Externally Validated Tool for Predicting Cardiac Implantable Electronic Device Infections, and Its Cost-Utility Implications for Antimicrobial Envelope Use.
    Maclean E; Mahtani K; Honarbakhsh S; Butcher C; Ahluwalia N; Dennis ASC; Creta A; Finlay M; Elliott M; Mehta V; Wijesuriya N; Shaikh O; Zaw Y; Ogbedeh C; Gautam V; Lambiase PD; Schilling RJ; Earley MJ; Moore P; Muthumala A; Sporton SCE; Hunter RJ; Rinaldi CA; Behar J; Martin C; Monkhouse C; Chow A
    Circ Arrhythm Electrophysiol; 2024 Mar; 17(3):e012446. PubMed ID: 38258308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.